MX2020000213A - Nueva composicion de forma de dosificacion oral de enzalutamida y metodo de fabricacion de la misma. - Google Patents
Nueva composicion de forma de dosificacion oral de enzalutamida y metodo de fabricacion de la misma.Info
- Publication number
- MX2020000213A MX2020000213A MX2020000213A MX2020000213A MX2020000213A MX 2020000213 A MX2020000213 A MX 2020000213A MX 2020000213 A MX2020000213 A MX 2020000213A MX 2020000213 A MX2020000213 A MX 2020000213A MX 2020000213 A MX2020000213 A MX 2020000213A
- Authority
- MX
- Mexico
- Prior art keywords
- enzalutamide
- manufacturing
- dosage form
- oral dosage
- novel composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201721023465 | 2017-07-04 | ||
| PCT/IB2017/057273 WO2019008426A1 (fr) | 2017-07-04 | 2017-11-21 | Nouvelle composition de forme galénique orale d'enzalutamide et procédé de fabrication de celle-ci |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020000213A true MX2020000213A (es) | 2020-08-17 |
Family
ID=64950639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020000213A MX2020000213A (es) | 2017-07-04 | 2017-11-21 | Nueva composicion de forma de dosificacion oral de enzalutamida y metodo de fabricacion de la misma. |
Country Status (7)
| Country | Link |
|---|---|
| BR (1) | BR112020000207A2 (fr) |
| CL (1) | CL2020000017A1 (fr) |
| MX (1) | MX2020000213A (fr) |
| PH (1) | PH12020500045A1 (fr) |
| RU (1) | RU2020105102A (fr) |
| WO (1) | WO2019008426A1 (fr) |
| ZA (1) | ZA202000609B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR118925A1 (es) * | 2020-05-13 | 2021-11-10 | Novocap S A | Solución líquida concentrada de antiandrógenos no esteroideos y procedimiento para preparar la solución |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201891397A1 (ru) * | 2014-02-05 | 2019-03-29 | Лек Фармасьютикалз Д.Д. | Твердые фармацевтические композиции антагонистов рецепторов андрогенов |
-
2017
- 2017-11-21 RU RU2020105102A patent/RU2020105102A/ru unknown
- 2017-11-21 BR BR112020000207-0A patent/BR112020000207A2/pt unknown
- 2017-11-21 WO PCT/IB2017/057273 patent/WO2019008426A1/fr active Application Filing
- 2017-11-21 MX MX2020000213A patent/MX2020000213A/es unknown
-
2020
- 2020-01-03 PH PH12020500045A patent/PH12020500045A1/en unknown
- 2020-01-03 CL CL2020000017A patent/CL2020000017A1/es unknown
- 2020-01-29 ZA ZA2020/00609A patent/ZA202000609B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019008426A1 (fr) | 2019-01-10 |
| BR112020000207A2 (pt) | 2020-07-07 |
| PH12020500045A1 (en) | 2020-11-09 |
| CL2020000017A1 (es) | 2020-05-22 |
| RU2020105102A (ru) | 2021-08-04 |
| ZA202000609B (en) | 2021-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018007704A (es) | Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante. | |
| SG10201804868PA (en) | Compounds for the inhibition of indoleamine-2,3-dioxygenase | |
| MY196319A (en) | Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders | |
| MX2015010921A (es) | Compuestos de carbazol utiles como inhibidores de bromodominio. | |
| EA201690962A1 (ru) | Составы | |
| EP3705118A4 (fr) | Composition pour forme posologique solide orale présentant une désintégration améliorée et son procédé de préparation | |
| TR201821116A2 (tr) | POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ | |
| MX2017008386A (es) | Administración específica del sitio de un inhibidor de btk. | |
| IN2013MU03583A (fr) | ||
| MX2021002322A (es) | Nuevos metodos. | |
| SG10201902203VA (en) | Eutectic formulations of cyclobenzaprine hydrochloride | |
| IN2014MU00303A (fr) | ||
| PH12016501686A1 (en) | Pharmaceutical compositions of sitagliptin | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| MX2017015137A (es) | Composicion farmaceutica oral de dosis diaria de isotretinoin. | |
| MX2018012618A (es) | Composiciones farmaceuticas orales de mesalazina. | |
| EA201791009A1 (ru) | Композиции, содержащие циклоспорин | |
| CR20210158A (es) | Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| MX2021003862A (es) | Formas cristalinas y procesos de besilato de lenvatinib. | |
| TR201721505A2 (tr) | Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon | |
| MX366829B (es) | Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. | |
| MX2017008983A (es) | Composición farmaceútica de sulfonamida. | |
| TR201722603A2 (tr) | Metformi̇n ve si̇tagli̇pti̇n i̇çeren sicak eri̇tme ekstrüzyonu i̇le gerçekleşti̇ri̇len tablet formülasyonlari | |
| PH12020500045A1 (en) | Novel composition of enzalutamide oral dosage form and method of manufacturing thereof |